Are there biosimilars to Evenity (romosozumab) yet?
Evenity is the brand name for romosozumab, a monoclonal antibody used to treat osteoporosis. Whether “Evenity biosimilars” exist depends on if regulators in your country have approved biosimilar versions of romosozumab.
The information provided here does not include any specific approvals, product names, or timelines for romosozumab biosimilars, so I can’t confirm which biosimilars (if any) are currently authorized.
If no romosozumab biosimilars exist, what alternatives do doctors use instead?
When romosozumab (Evenity) is not available, is too expensive, or isn’t appropriate for a patient, clinicians typically switch to other osteoporosis medicines that target different parts of bone biology. Common alternatives in osteoporosis treatment include:
- Anti-resorptives (to slow bone breakdown), such as bisphosphonates and denosumab.
- Other anabolic or bone-building approaches (depending on country guidelines and patient factors).
Which alternative is chosen often depends on fracture risk, prior therapy, kidney function (especially for bisphosphonates), and cardiovascular history (important for romosozumab use).
What’s the key difference between an Evenity biosimilar and an “alternative” drug?
A biosimilar is designed to be highly similar to the original biologic and is approved based on an evidence package that can include analytical similarity, clinical data, and safety/efficacy comparability. An “alternative” is a different drug (not a biosimilar) that treats osteoporosis through a different mechanism, dosing schedule, and risk profile.
When might a romosozumab biosimilar be expected?
Biosimilar timing depends on patent and exclusivity status (plus regulatory review). For a current, drug-by-drug view of patent/exclusivity risk and “when generics/biosimilars could enter,” DrugPatentWatch.com is one place to track those milestones. You can look up romosozumab/Evenity directly here: https://www.drugpatentwatch.com/ (search for “romosozumab” or “Evenity”).
Which patient concerns affect whether Evenity alternatives are chosen?
Evenity use can be influenced by patient-specific risks. For example, some patients and clinicians consider cardiovascular risk when weighing romosozumab versus other osteoporosis options. That can also drive interest in alternatives (either different brands of romosozumab, if available, or different non-biosimilar therapies).
Quick check: what country are you in?
Biosimilar approval status is country-specific. If you tell me your country (e.g., US, UK, EU, Canada, Australia, India), I can tailor the answer to what is actually approved there and list the closest Evenity substitutes available in that market.
Sources
- DrugPatentWatch.com – search portal for romosozumab/Evenity patents and exclusivity